CY2016044I1 - Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg - Google Patents

Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg

Info

Publication number
CY2016044I1
CY2016044I1 CY2016044C CY2016044C CY2016044I1 CY 2016044 I1 CY2016044 I1 CY 2016044I1 CY 2016044 C CY2016044 C CY 2016044C CY 2016044 C CY2016044 C CY 2016044C CY 2016044 I1 CY2016044 I1 CY 2016044I1
Authority
CY
Cyprus
Prior art keywords
liquid form
pharmaceutical preparation
igg antibodies
stable pharmaceutical
stable
Prior art date
Application number
CY2016044C
Other languages
English (en)
Other versions
CY2016044I2 (el
Original Assignee
Abbvie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotechnology Ltd filed Critical Abbvie Biotechnology Ltd
Publication of CY2016044I1 publication Critical patent/CY2016044I1/el
Publication of CY2016044I2 publication Critical patent/CY2016044I2/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CY2016044C 2001-11-08 2016-12-09 Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg CY2016044I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33750901P 2001-11-08 2001-11-08
PCT/US2002/036093 WO2003039485A2 (en) 2001-11-08 2002-11-08 Stable liquid pharmaceutical formulation of igg antibodies

Publications (2)

Publication Number Publication Date
CY2016044I1 true CY2016044I1 (el) 2017-07-12
CY2016044I2 CY2016044I2 (el) 2017-07-12

Family

ID=23320826

Family Applications (1)

Application Number Title Priority Date Filing Date
CY2016044C CY2016044I2 (el) 2001-11-08 2016-12-09 Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg

Country Status (17)

Country Link
US (3) US20030138417A1 (el)
EP (1) EP1441589B1 (el)
JP (2) JP5290489B2 (el)
KR (1) KR100913714B1 (el)
CN (1) CN1292655C (el)
AT (1) ATE556591T1 (el)
AU (1) AU2002363339B2 (el)
CA (1) CA2466034C (el)
CY (1) CY2016044I2 (el)
DK (1) DK1441589T3 (el)
ES (1) ES2392073T3 (el)
HK (1) HK1074750A1 (el)
IL (2) IL161677A0 (el)
LU (1) LU93314I2 (el)
NZ (1) NZ532896A (el)
PT (1) PT1441589E (el)
WO (1) WO2003039485A2 (el)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
US20040208870A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CA2519408C (en) 2003-04-04 2011-01-18 Genentech, Inc. High concentration antibody and protein formulations
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
ATE459374T1 (de) * 2003-11-28 2010-03-15 Micromet Ag Polypeptide enthaltende zusammensetzungen
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
NL1027975C2 (nl) 2004-01-09 2005-12-23 Pfizer Antilichamen tegen MAdCAM.
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
TW200638943A (en) * 2005-01-28 2006-11-16 Wyeth Corp Stabilized liquid polypeptide formulations
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2012200203B2 (en) * 2005-03-08 2014-07-03 Pfizer Products Inc. Anti-CTLA-4 Antibody Compositions
AU2006220829C1 (en) * 2005-03-08 2024-02-01 Pfizer Products Inc. Anti-CTLA-4 antibody compositions
AU2014240252B2 (en) * 2005-03-08 2016-10-06 Pfizer Products Inc Anti-CTLA-4 Antibody Compositions
HUE027096T2 (en) 2005-03-25 2016-08-29 Regeneron Pharma VEGF antagonist formulations
EP1888637A2 (en) * 2005-05-19 2008-02-20 Amgen Inc. Compositions and methods for increasing the stability of antibodies
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
AU2006261920A1 (en) * 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
US20070190047A1 (en) * 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
WO2007033230A2 (en) * 2005-09-12 2007-03-22 Novimmune S.A. Anti-cd3 antibody formulations
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
EP1951757B1 (en) * 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP2029132A4 (en) 2006-01-25 2011-07-27 Taro Pharmaceuticals North America Inc ANTIHISTAMINE COMPOSITIONS AND THEIR USE
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
US9238687B2 (en) 2006-04-13 2016-01-19 Chugai Seiyaku Kabushiki Kaisha Method for recombinant production of a desired polypeptide using a mammalian cell co-expressing a taurine transporter polypeptide
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MEP39508A (en) 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
AU2016204760A1 (en) * 2006-04-26 2016-07-28 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2014268186C1 (en) * 2006-04-26 2017-12-07 Wyeth Llc Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2007149334A2 (en) 2006-06-16 2007-12-27 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
AU2012200284B2 (en) * 2006-10-06 2014-03-06 Amgen Inc. Stable Antibody Formulations
WO2008051363A2 (en) * 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
JP5577098B2 (ja) * 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
EP2135946B1 (en) 2007-03-15 2015-12-09 Chugai Seiyaku Kabushiki Kaisha Method for production of polypeptide
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2009009406A1 (en) * 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2194126B1 (en) 2007-10-15 2014-01-15 Chugai Seiyaku Kabushiki Kaisha Method of constructing cells with high productivity of foreign protein
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
DK2213746T3 (en) 2007-10-24 2015-08-03 Chugai Pharmaceutical Co Ltd CELL FOR USE IN THE PREPARATION OF exogenous protein, AND MANUFACTURING METHOD THAT USE CELL
EP2219602A1 (en) * 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
NZ586303A (en) * 2007-12-28 2012-03-30 Bioinvent Int Ab Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
EP2328607A1 (en) 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
WO2010031720A2 (en) 2008-09-19 2010-03-25 F. Hoffmann-La Roche Ag Novel antibody formulation
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2350649A4 (en) * 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
EP2403873A1 (en) 2009-03-05 2012-01-11 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
TW201039854A (en) * 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
US20120018338A1 (en) * 2009-03-30 2012-01-26 Hoffman-La Roche Inc. Method for avoiding glass fogging
WO2010123014A1 (ja) 2009-04-22 2010-10-28 中外製薬株式会社 異種タンパク質を高生産する細胞の作製方法
JP2012526121A (ja) * 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
CA2765220A1 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
CA2726232A1 (en) * 2009-07-16 2010-08-12 Arecor Limited Stable formulation of a therapeutic protein
WO2011026117A1 (en) 2009-08-31 2011-03-03 Facet Biotech Corporation Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients
LT2805731T (lt) * 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
WO2011028961A2 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP2473191B1 (en) * 2009-09-04 2017-08-23 XOMA Technology Ltd. Antibody coformulations
EP2470901A1 (en) 2009-10-30 2012-07-04 Abbott Biotherapeutics Corp. Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
JP2013515754A (ja) * 2009-12-29 2013-05-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規な抗体製剤
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
US20120294866A1 (en) * 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2011109365A2 (en) * 2010-03-01 2011-09-09 Progenics Pharmaceuticals, Inc. Concentrated protein formulations and uses thereof
DK2542257T3 (en) 2010-03-01 2017-10-16 Bayer Healthcare Llc OPTIMIZED MONOCLONAL ANTIBODIES AGAINST Tissue FACTOR ROAD INHIBITOR (TFPI)
CN107080838A (zh) 2010-06-04 2017-08-22 惠氏有限责任公司 疫苗制剂
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
AR083034A1 (es) 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
JO3400B1 (ar) 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
PT2635601T (pt) 2010-11-04 2016-09-27 Boehringer Ingelheim Int Anticorpos anti-il-23
KR101841527B1 (ko) 2010-11-11 2018-03-23 애브비 바이오테크놀로지 리미티드 개선된 고농도 항－ＴＮＦα 항체 액체 제형
EP2471554A1 (en) * 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
JP2014503555A (ja) 2011-01-13 2014-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用
AU2012237026A1 (en) 2011-03-25 2013-10-24 Genentech, Inc. Novel protein purification methods
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
SG10201604104PA (en) 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
ES2732243T3 (es) * 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
EP2844284A1 (en) 2012-05-03 2015-03-11 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
CN104427974B (zh) 2012-05-18 2018-03-23 基因泰克公司 高浓度单克隆抗体配制剂
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
BR112015000203A2 (pt) * 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EA029215B1 (ru) * 2012-09-07 2018-02-28 Кохерус Байосайенсис, Инк. Стабильные водные составы адалимумаба
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2904527A1 (en) 2013-03-15 2014-09-18 Abbvie Biotechnology Ltd. Anti-cd25 antibodies and their uses
CA2902289A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Low concentration antibody formulations
AU2014240045A1 (en) 2013-03-15 2015-09-10 Dyax Corp. Anti-plasma kallikrein antibodies
BR112015023084A2 (pt) 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
JP6590803B2 (ja) 2013-11-21 2019-10-16 ゲンマブ エー／エス 抗体−薬物コンジュゲート凍結乾燥製剤
PL3096798T3 (pl) 2014-01-21 2021-07-26 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego
CA2942713A1 (en) 2014-03-27 2015-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CA2946230A1 (en) * 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
SG11201609706VA (en) 2014-06-23 2017-01-27 Novartis Ag Site specific protein modifications
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
BR112017008160A8 (pt) 2014-10-24 2023-04-11 Merck Sharp & Dohme Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
KR102636726B1 (ko) 2014-11-07 2024-02-13 에프. 호프만 라-로셰 엘티디 향상된 il-6 항체
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
EP3292147A1 (en) 2015-05-07 2018-03-14 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
EA201891388A1 (ru) 2015-12-11 2018-11-30 Дайэкс Корп. Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2017121867A1 (en) 2016-01-13 2017-07-20 Genmab A/S Formulation for antibody and drug conjugate thereof
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
WO2018027195A1 (en) * 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
EP3533441A4 (en) 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2018181876A1 (ja) * 2017-03-31 2018-10-04 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MX2019013072A (es) 2017-05-02 2019-12-16 Merck Sharp & Dohme Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
US11654194B2 (en) * 2017-05-16 2023-05-23 Jiangsu Hengrui Medicine Co., Ltd. PD-L1 antibody pharmaceutical composition and use thereof
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CU20200002A7 (es) 2017-07-14 2020-11-30 Pfizer Anticuerpos contra madcam
BR112020004325A2 (pt) 2017-09-05 2020-10-06 Merck Sharp & Dohme Corp. compostos para reduzir a viscosidade de formulações biológicas
US20200255496A1 (en) * 2017-09-18 2020-08-13 Amgen Inc. Vegfr-fc fusion protein formulations
SI3727423T1 (sl) 2017-12-22 2024-08-30 Novartis Ag Zdravljenje metaboličnih motenj z različicami fgf21
BR112020022610A2 (pt) 2018-05-10 2021-02-09 Regeneron Pharmaceuticals, Inc. proteína de fusão de receptor de vegf de alta concentração que contém formulações
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020109978A1 (en) 2018-11-26 2020-06-04 Novartis Ag Lpl-gpihbp1 fusion polypeptides
EP3888678A4 (en) * 2018-11-29 2022-02-16 Harbour Biomed Therapeutics Limited PREPARATION OF AN ANTI-PD-L1 ANTIBODY
EP3914282A1 (en) 2019-01-25 2021-12-01 Ospedale San Raffaele S.r.l. Inhibitor of dux4 and uses thereof
EP3996740A4 (en) * 2019-07-12 2023-07-05 Contrafect Corporation THERAPEUTIC PROTEIN FORMULATIONS INCLUDING ANTIBODIES AND THEIR USES
GB201913697D0 (en) 2019-09-23 2019-11-06 King S College London DAP10/DAP12 fusion polypeptides
MX2022008655A (es) * 2020-01-13 2022-09-23 Aptevo Res & Development Llc Metodos y composiciones para prevenir la adsorcion de proteinas terapeuticas en componentes del sistema de administracion de farmacos.
GB202003277D0 (en) 2020-03-06 2020-04-22 King S College London Therapeutic agents
JP2023525898A (ja) * 2020-05-19 2023-06-19 エフ． ホフマン－ラ ロシュ アーゲー 非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
GB202007655D0 (en) 2020-05-22 2020-07-08 King S College London Chimeric nkg2d protein
CA3212856A1 (en) 2021-03-23 2022-09-29 John Maher Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof
AU2023236910A1 (en) 2022-03-14 2024-08-01 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
GB202214120D0 (en) 2022-09-27 2022-11-09 King S College London Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
JPH03504605A (ja) 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
EP0448605A4 (en) * 1988-12-15 1991-11-21 Invitron Corporation Use of basic amino acids to solubilize immunoglobulins
EP0465513A1 (en) 1989-03-27 1992-01-15 Centocor, Inc. FORMULATIONS FOR STABILIZING OF IgM ANTIBODIES
US6165467A (en) * 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997004801A1 (en) * 1995-07-27 1997-02-13 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
TR200802278T2 (tr) 1999-03-25 2008-08-21 Abbott Gmbh & Co. Kg Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler.
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies

Also Published As

Publication number Publication date
EP1441589A4 (en) 2007-07-04
US20110318343A1 (en) 2011-12-29
US20110070231A1 (en) 2011-03-24
DK1441589T3 (da) 2012-08-06
CA2466034A1 (en) 2003-05-15
JP2005508981A (ja) 2005-04-07
CY2016044I2 (el) 2017-07-12
LU93314I2 (el) 2019-11-20
HK1074750A1 (en) 2005-11-25
NZ532896A (en) 2007-08-31
US20030138417A1 (en) 2003-07-24
EP1441589A2 (en) 2004-08-04
JP2011068675A (ja) 2011-04-07
WO2003039485A3 (en) 2004-02-12
US8465739B2 (en) 2013-06-18
KR100913714B1 (ko) 2009-08-24
IL161677A0 (en) 2004-09-27
CN1292655C (zh) 2007-01-03
EP1441589B1 (en) 2012-05-09
JP5290489B2 (ja) 2013-09-18
KR20050044365A (ko) 2005-05-12
PT1441589E (pt) 2012-08-13
AU2002363339B2 (en) 2008-02-07
CA2466034C (en) 2012-12-18
ES2392073T3 (es) 2012-12-04
IL161677A (en) 2010-06-16
ATE556591T1 (de) 2012-05-15
CN1612689A (zh) 2005-05-04
WO2003039485A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
CY2016044I1 (el) Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg
CY2019022I1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
CY2011003I2 (el) Φαρμακευτικα προϊοντα σε διαλυμα που περιεχουν αντισωμα
IL158802A0 (en) Stable liquid formulations of antibodies
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
ATE555809T1 (de) Pharmezeutische anti-tnf-alpha antikörper formulierung
NO20055774D0 (no) Flytende stabiliserte proteinformuleringer i belagte farmasoytiske beholdere
DK1572946T3 (da) Terapeutisk humant monoklonalt anti-IL-1R1-antistof
AU2002351239A8 (en) Antibody to latent membrane proteins and uses thereof
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
NO20033387L (no) Modifiserte antistoffer og fremgangsmåter for anvendelse
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
NO20033418L (no) Immunregulatoriske antistoffer og anvendelse derav
DE60331598D1 (de) Verabreichung von anti-tnf-alpha f(ab')2 antikörper-fragmenten
NO20015711D0 (no) Farmasöytiske preparater inneholdende anti-Fas-antistoff
FI20010614A0 (fi) Pienien neste-erien kvantitatiivinen annostelu
MA27184A1 (fr) Dosage d'anticorps anti-ingap
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
GB0119497D0 (en) Expression of modified antibodies in avian cells
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
EE200300377A (et) Loomulikud HI-viiruse vastased antikehad
FR2826244B1 (fr) Dizainier du saint sacrement